You can be on Entrepreneur’s cover!

This Is Y Combinator's Next Hot Area of Investment For the first time, the accelerator program is actively recruiting startups outside the tech space.

By Laura Entis

entrepreneur daily

Opinions expressed by Entrepreneur contributors are their own.

Until now, Y Combinator -- the prestigious accelerator program that vaulted some of Silicon Valley's most buzzed about companies, including Drobox, Airbnb and Reddit - was primarily a tech incubator.

But the accelerator is expanding its horizons. This year, for the very first time, it is pursuing health-tech startups, Reuters reported. "It's the right time for us to try health care," Sam Altman, Y Combinator's president, said, noting that there's been a recent and significant decrease in both "cost and cycle time."

Related: Google Wants to Build a Model of Perfect Human Health

While Altman conceded the move may unsettle venture capitalists, at least initially ("When we move into a new area, [they] usually don't like it," he said), it's not that big of a surprise. Venture capitalists across the country are suddenly pouring money into health technology companies. In 2013, according to the National Venture Capital Association, the biotechnology industry received 15.6 percent of all venture funding. Only the software industry, at 30.2 percent, took in a larger slice.

In addition, 2013 saw digital health startups, which include companies developing wearable tech and software/hardware solutions for specific diseases and conditions, take in almost $2 billion in funding, according to the venture fund Rock Health.

Related: 5 Startups to Watch at Y Combinator's Demo Day

While it was a record year for funding in the space, this year's funding total is going to blow last year's away: According Rock Health's 2014 mid-year report, the first half of 2014 saw digital health companies take in a whopping $2.2 billion.

Altman took over as president of Y Combinator when the accelerator's co-founder, Paul Graham, stepped down in February. On Tuesday, the first class of Y Combinator startups under Altman's tenure graduated from the program. They included a high percentage of health and biotech startups including The Immunity Project (a startup attempting to develop an HIV vaccine), Glowing Plant (which develops genetically engineered plants that function as air purifiers), UBiome (a startup that analyzes bacteria) and Ginko BioWorks (which is currently working to treat antibiotic resistant germs).

Related: 5 Questions Every Startup Should Ask Before Choosing an Incubator

Laura Entis is a reporter for Fortune.com's Venture section.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Growing a Business

To Achieve Sustainable Success, You Need to Stop Focusing on Disruption. Here's Why — and What You Must Focus on Instead.

Instead of zeroing in solely on disruptive innovation, embrace a pragmatic approach to innovation, recognizing and leveraging the potential within ongoing industry shifts.

Business News

Mark Zuckerberg Says This CEO Is the 'Taylor Swift' of Tech

Meta's CEO posed with Nvidia CEO Jensen Huang on Instagram Wednesday.

Real Estate

3 Emerging Trends Shaping the Future of Real Estate

These three innovations are reshaping the real estate industry — discover tips for effectively covering these trends.

Leadership

What We Have to Gain By Talking About Grief and Loss At Work

I lost my husband to cancer during Covid — here's how it changed how I lead at work.

Side Hustle

This Mom Started a Side Hustle After a 'Shocking' Realization in the Toy Aisle. Her Product Was in Macy's Within the Year — Seeing Nearly $350,000 in Sales.

Elenor Mak, now founder of Jilly Bing, didn't plan to start a business — but the search for a doll that looked like her daughter inspired her to do just that.

Fundraising

Avoid These 9 Pitch Deck Mistakes When Asking Others For Money

Crafting an efficient pitch deck requires serious effort, but at least it's not wandering in the dark since certain rules are shaped by decades of relationships between startups and investors.